Cipla500087Pharmaceuticals
Cipla reported largely in-line Q2 revenue but missed profit estimates, with US sales roughly steady
By ScoutQuest · · 1 min read
- Revenue this quarter
- 7,400 crore rupees
- Revenue estimate
- 7,498 crore rupees
- EBITDA margin
- 18.7 percent
- Margin estimate
- 18.3 percent
- Profit
- 877 crore rupees
Heard on business television between 14:33:40 - 14:36:40 IST.
- Revenue came in at around ₹7,400 crore versus a poll estimate of ₹7,498 crore.
- EBITDA margin was 18.7% versus estimate of 18.3%.
- Profit of around ₹877 crore missed street expectations.
- India business grew about 12%, in line with the 10-12% expected growth.
- US sales were $170 million versus estimate of $172 million, broadly maintained despite pressure from Lenalidomide and Revlimid generic opportunity dilution.
- Emerging markets in Europe were flat, while API and other segments fell around 59%.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Cipla
Cipla reported modest Q2 numbers but maintained its US revenue and EBITDA margin guidance, prompting mixed brokerage reactions
28 Oct 2026
Cipla posts audio recording of Q2/H1 FY27 earnings conference call on its website
27 Oct 2026
Cipla's Q2 results were largely in line with estimates, with a dip in profit and muted US sales due to supply issues
27 Oct 2026
Source: Live TV News Channel · 27 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.